Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody…
Survey: Fire and Water Leaks Worry Hong Kongers, But Nearly One-Quarter Embrace Optimism Bias, Over 70% See Importance, Yet 60% Stay Uninsured, Blue Cross Strengthens Awareness with Upgraded "HomeSafe Protection Plus"
HONG KONG, April 1, 2026 /PRNewswire/ — A "Hong Kong Home Insurance…